Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
Summary
The Publisher's Medical Devices sector report, “Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Rapid Tests & Point of Care (POC) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Retrovirus Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Reasons to Buy
The report enables you to:
Summary
The Publisher's Medical Devices sector report, “Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Retrovirus Rapid Tests & Point of Care (POC) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Retrovirus Rapid Tests & Point of Care (POC) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Retrovirus Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Retrovirus Rapid Tests & Point of Care (POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Retrovirus Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1.1 List of Tables1.2 List of Figures
2 Introduction
2.1 Retrovirus Rapid Tests & Point of Care (POC) Overview
- Retrovirus Rapid Tests & Point of Care are the rapid diagnostic tests used to detect the HIV 1 and HIV 2 (human immunodeficiency virus) viruses and generate results immediately in a limited resource setting.
3 Products under Development
3.1 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development
3.2 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Territory
3.3 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Regulatory Path
3.4 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Estimated Approval Date
4 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products under Development by Companies
4.1 Retrovirus Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development
4.2 Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development
5 Retrovirus Rapid Tests & Point of Care (POC) Companies and Product Overview
5.1 Access Bio Inc Company Overview
5.1.1 Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Akers Biosciences Inc Company Overview
5.2.1 Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Aldatu Biosciences Inc Company Overview
5.3.1 Aldatu Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Alere Inc Company Overview
5.4.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Altratech Ltd Company Overview
5.5.1 Altratech Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.6 BBB Technologies Inc Company Overview
5.6.1 BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Beijing Wantai Biological Pharmacy Enterprise Co Ltd Company Overview
5.7.1 Beijing Wantai Biological Pharmacy Enterprise Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.8 Binx Health Inc Company Overview
5.8.1 Binx Health Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Bio-AMD Inc Company Overview
5.9.1 Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview
5.10 Biocartis Group NV Company Overview
5.10.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview
5.11 BioHelix Corp Company Overview
5.11.1 BioHelix Corp Pipeline Products & Ongoing Clinical Trials Overview
5.12 Calypte Biomedical Corporation Company Overview
5.12.1 Calypte Biomedical Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.13 Centre International de Reference Chantal Biya Company Overview
5.13.1 Centre International de Reference Chantal Biya Pipeline Products & Ongoing Clinical Trials Overview
5.14 Cepheid Company Overview
5.14.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview
5.15 Chembio Diagnostic Systems Inc Company Overview
5.15.1 Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
5.16 CrossLife Technologies Inc Company Overview
5.16.1 CrossLife Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 Daktari Diagnostics, Inc. Company Overview
5.17.1 Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.18 Diagnostics For All Inc Company Overview
5.18.1 Diagnostics For All Inc Pipeline Products & Ongoing Clinical Trials Overview
5.19 Diagnostics for the Real World (Europe) Ltd Company Overview
5.19.1 Diagnostics for the Real World (Europe) Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.20 Endeavor Sciences Inc Company Overview
5.20.1 Endeavor Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.21 Epinex Diagnostics Inc Company Overview
5.21.1 Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 ERBA Molecular Ltd Company Overview
5.22.1 ERBA Molecular Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.23 GAIA Medical Institute LLC Company Overview
5.23.1 GAIA Medical Institute LLC Pipeline Products & Ongoing Clinical Trials Overview
5.24 genedrive plc Company Overview
5.24.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview
5.25 Group K Diagnostics Company Overview
5.25.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.26 HeatFlow Technologies Inc Company Overview
5.26.1 HeatFlow Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.27 Imperial College London Company Overview
5.27.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
5.28 Jinvator Bio Med GmbH Company Overview
5.28.1 Jinvator Bio Med GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.29 Johns Hopkins University Company Overview
5.29.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
5.30 Labsystems Diagnostics Oy Company Overview
5.30.1 Labsystems Diagnostics Oy Pipeline Products & Ongoing Clinical Trials Overview
5.31 Micronics Inc Company Overview
5.31.1 Micronics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.32 Molbio Diagnostics Pvt Ltd Company Overview
5.32.1 Molbio Diagnostics Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.33 Nanobiosym Inc Company Overview
5.33.1 Nanobiosym Inc Pipeline Products & Ongoing Clinical Trials Overview
5.34 NeuMoDx Molecular Inc Company Overview
5.34.1 NeuMoDx Molecular Inc Pipeline Products & Ongoing Clinical Trials Overview
5.35 Newmark Diagnostics LLC Company Overview
5.35.1 Newmark Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.36 Northwestern University Company Overview
5.36.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
5.37 Orangelife Company Overview
5.37.1 Orangelife Pipeline Products & Ongoing Clinical Trials Overview
5.38 Osel Inc Company Overview
5.38.1 Osel Inc Pipeline Products & Ongoing Clinical Trials Overview
5.39 QuantuMDx Group Ltd Company Overview
5.39.1 QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.40 Quidel Corp Company Overview
5.40.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview
5.41 Radisens Diagnostics Ltd Company Overview
5.41.1 Radisens Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.42 Rheonix Inc Company Overview
5.42.1 Rheonix Inc Pipeline Products & Ongoing Clinical Trials Overview
5.43 Roche Diagnostics International Ltd Company Overview
5.43.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.44 Sedia Biosciences Corp Company Overview
5.44.1 Sedia Biosciences Corp Pipeline Products & Ongoing Clinical Trials Overview
5.45 TheoremDx Inc Company Overview
5.45.1 TheoremDx Inc Pipeline Products & Ongoing Clinical Trials Overview
5.46 Trinity Biotech Plc Company Overview
5.46.1 Trinity Biotech Plc Pipeline Products & Ongoing Clinical Trials Overview
5.47 University of Washington Company Overview
5.47.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview
5.48 UrSure Inc Company Overview
5.48.1 UrSure Inc Pipeline Products & Ongoing Clinical Trials Overview
5.49 Wave 80 Biosciences Inc Company Overview
5.49.1 Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.50 Yaathum Biotech Pvt Ltd Company Overview
5.50.1 Yaathum Biotech Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
6 Retrovirus Rapid Tests & Point of Care (POC) - Recent Developments
6.1 Nov 04, 2019: Chembio Diagnostics receives WHO Prequalification Approval for HIV Self-Test
6.2 Oct 30, 2019: Quidel reports third quarter 2019 financial results
6.3 Oct 17, 2019: Chembio Diagnostics receives WHO prequalification approval for Malaysia facility
6.4 Oct 16, 2019: Trinity Biotech announces results for Q3, 2019
6.5 Oct 15, 2019: Johnson & Johnson reports 2019 Third-Quarter Results
6.6 Sep 30, 2019: Johnson & Johnson appoints Carlton Lawson to area Managing Director, Consumer, Northern Europe
6.7 Sep 19, 2019: INSTI now available for expanded point-of-care use in Canada
6.8 Sep 16, 2019: Omega Diagnostics Group: Update on VISITECT CD4 Advanced Disease
6.9 Sep 05, 2019: Biocartis announces H1 2019 results
6.10 Aug 20, 2019: First purchase order for VISITECT CD4 advanced disease test
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact Us
7.4 Disclaimer
List of Tables
Table 1: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development
Table 2: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Territory
Table 3: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Regulatory Path
Table 4: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Estimated Approval Date
Table 5: Retrovirus Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development
Table 6: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development
Table 7: Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 8: CareUS HIV Rapid Diagnostic Test - Product Status
Table 9: CareUS HIV Rapid Diagnostic Test - Product Description
Table 10: Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 11: PIFA HIV 1+2 Rapid Assay - Product Status
Table 12: PIFA HIV 1+2 Rapid Assay - Product Description
Table 13: Aldatu Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 14: PANDAA HIV6 - Product Status
Table 15: PANDAA HIV6 - Product Description
Table 16: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 17: Alere q HIV-1/2 VL Plasma Assay - Product Status
Table 18: Alere q HIV-1/2 VL Plasma Assay - Product Description
Table 19: Altratech Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Point-Of-Care Test - HIV Infection - Product Status
Table 21: Point-Of-Care Test - HIV Infection - Product Description
Table 22: BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Mobile RDT Reader - HIV1/2 Test - Product Status
Table 24: Mobile RDT Reader - HIV1/2 Test - Product Description
Table 25: Beijing Wantai Biological Pharmacy Enterprise Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Urine Based Rapid HIV Test - Product Status
Table 27: Urine Based Rapid HIV Test - Product Description
Table 28: Binx Health Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Atlas io System - HIV Assay - Product Status
Table 30: Atlas io System - HIV Assay - Product Description
Table 31: Bio-AMD Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Digital Strip Reader - HIV Test - Product Status
Table 33: Digital Strip Reader - HIV Test - Product Description
Table 34: Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Idylla Viral Load Assay - HIV - Product Status
Table 36: Idylla Viral Load Assay - HIV - Product Description
Table 37: BioHelix Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 38: IsoAmp Assay - HIV - Product Status
Table 39: IsoAmp Assay - HIV - Product Description
Table 40: IsoAmp HIV-1 Quantitative Assay - Product Status
Table 41: IsoAmp HIV-1 Quantitative Assay - Product Description
Table 42: Calypte Biomedical Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 43: Aware 2 HIV-1/2 - Product Status
Table 44: Aware 2 HIV-1/2 - Product Description
Table 45: Aware HIV-1/2 OMT - Product Status
Table 46: Aware HIV-1/2 OMT - Product Description
Table 47: Centre International de Reference Chantal Biya Pipeline Products & Ongoing Clinical Trials Overview
Table 48: Point-Of-Care Diagnostic Test - HIV-1 - Product Status
Table 49: Point-Of-Care Diagnostic Test - HIV-1 - Product Description
Table 50: Cepheid Pipeline Products & Ongoing Clinical Trials Overview
Table 51: GeneXpert Omni - HIV-1 Qualitative Test - Product Status
Table 52: GeneXpert Omni - HIV-1 Qualitative Test - Product Description
Table 53: GeneXpert Omni - HIV-1 Viral Load Test - Product Status
Table 54: GeneXpert Omni - HIV-1 Viral Load Test - Product Description
Table 55: Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 56: DPP HIV Ag-Ab Assay - Product Status
Table 57: DPP HIV Ag-Ab Assay - Product Description
Table 58: Next Generation DPP HIV ½ Oral Fluid Assay - Product Status
Table 59: Next Generation DPP HIV ½ Oral Fluid Assay - Product Description
Table 60: Sure Check HIV OTC Assay - Product Status
List of Figures
Figure 1: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Stage of Development
Figure 2: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Territory
Figure 3: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Regulatory Path
Figure 4: Retrovirus Rapid Tests & Point of Care (POC) -Pipeline Products by Estimated Approval Date
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Access Bio Inc
- Akers Biosciences Inc
- Aldatu Biosciences Inc
- Alere Inc
- Altratech Ltd
- BBB Technologies Inc
- Beijing Wantai Biological Pharmacy Enterprise Co Ltd
- Binx Health Inc
- Bio-AMD Inc
- Biocartis Group NV
- BioHelix Corp
- Calypte Biomedical Corporation
- Centre International de Reference Chantal Biya
- Cepheid
- Chembio Diagnostic Systems Inc
- CrossLife Technologies Inc
- Daktari Diagnostics, Inc.
- Diagnostics For All Inc
- Diagnostics for the Real World (Europe) Ltd
- Endeavor Sciences Inc
- Epinex Diagnostics Inc
- ERBA Molecular Ltd
- GAIA Medical Institute LLC
- genedrive plc
- Group K Diagnostics
- HeatFlow Technologies Inc
- Imperial College London
- Jinvator Bio Med GmbH
- Johns Hopkins University
- Labsystems Diagnostics Oy
- Micronics Inc
- Molbio Diagnostics Pvt Ltd
- Nanobiosym Inc
- NeuMoDx Molecular Inc
- Newmark Diagnostics LLC
- Northwestern University
- Orangelife
- Osel Inc
- QuantuMDx Group Ltd
- Quidel Corp
- Radisens Diagnostics Ltd
- Rheonix Inc
- Roche Diagnostics International Ltd
- Sedia Biosciences Corp
- TheoremDx Inc
- Trinity Biotech Plc
- University of Washington
- UrSure Inc
- Wave 80 Biosciences Inc
- Yaathum Biotech Pvt Ltd
![In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image](http://www.researchandmarkets.com/product_images/12002/12002788_60px_jpg/invitro_diagnostics_market.jpg)
